1 study found for:    EB1010
Show Display Options
Rank Status Study
1 Active, not recruiting A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Condition: Major Depressive Disorder
Interventions: Drug: EB-1010 25mg BID;   Drug: SSRI Active;   Drug: EB-1010 50mg BID;   Drug: Placebo

Indicates status has not been verified in more than two years